ClinicalTrials.gg
CompletedNCT03895762OASISUpdated May 5, 2022

Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

An observational study in Breakthrough Cancer Pain, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
143
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Cancer Pain with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Cancer Pain · Korea, Republic of.

Started
2017
with 1 other
Observational
2 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
A.Menarini Asia-Pacific Holdings Pte Ltd

Among the 15 studies in Cancer Pain with a site in Korea, Republic of, this one is one of 2 that started in 2017, is one of 2 observational ones, and was the 14th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

None of the 15 studies in Cancer Pain with a site in Korea, Republic of is open now. The open studies under Cancer Pain, anywhere →

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Cancer Pain with a site in Korea, Republic of as a file.
02

Study summary

The purpose of this observational study is:

To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings and supplement and expand the previous cross-sectional survey results.

Read the detailed description

This is a multicenter, non-interventional, single-arm, non-randomized observational study designed to collect the efficacy, safety, and tolerability data of Abstral ODT for the treatment of breakthrough cancer pain in cancer patients in real-world outpatient and inpatient clinical settings.

As the purpose of this study is to investigate the efficacy and safety of Abstral ODT in routine clinical practice, drug prescription and treatment will be determined according to the medical judgment of the investigator, regardless of enrollment to this study. During the patient's visit to the institution, Abstral ODT will be prescribed according to the judgment of the investigator, and study participation will be suggested for this patient. Whether to participate in this study or not will not affect the patient's treatment (physician's prescription or diagnostic and therapeutic decision).

Due to the non-interventional observational nature of this study, there will be no visits or procedures to be performed mandatorily according to the protocol, and data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.

Status of successful dose titration for Abstral ODT will be determined according to the criteria in which dose titration is deemed successful when all of the following are met, and ineffective when one of the following is not met: no additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; Numeric Rating Scale scores at 30 and 60 min after administration is reduced by ≥2; adverse drug reactions are tolerable for the subject.The overall procedures of this study are as follows.

03

Conditions studied

  • Breakthrough Cancer Pain

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who have been regularly on treatment with opioids for cancer pain from before study initiation and have no prior treatment with Abstral ODT within 30 days prior to study initiation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Korean male and female adults at the age of 19 or older
  2. In patient with Breakthrough cancer pain in inpatient or outpatient settings,

    • Patient with minimally 1 attack per day for the last week
    • Uncontrolled Breakthrough cancer pain patient with previous treatment with other fentanyl based on Invenstigator's judgment or patient who had not satisfied with previous treatment with other fentanyl at patient's request
  3. Patient with opioid tolerance (treatment with at least 60 ㎎/day oral morphine, at least 25 mcg/hour transdermal fentanyl, at least 30 ㎎/day oxycodone, at least 8 ㎎/day oral hydromorphone, or other opioids at equivalent analgesic doses for 1 week or longer)
  4. Patient who has been on opioids for the treatment of background cancer pain
  5. Patient who did not administer Abstral ODT within 1 month prior to the baseline visit
  6. Patient who signs the data release consent to data use.

Exclusion criteria

Exclusion Criteria:

  1. Patient for whom Abstral ODT is based on its summary of product characteristics
  2. Patient who is considered by the investigator to be ineligible for study participation for other reasons
  3. Patient who is participating or participated in an opioid related clinical trial within 30 days prior to the baseline visit
  4. Patient with neuropathic pain attacks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
143 participants (actual)
Patient registry
No

Groups and cohorts

  • Abstral Oral Disintegrating Tablet (ODT)

    Abstral Oral Disintegrating Tablet (ODT)

    Drug: Abstral Oral Disintegrating Tablet (ODT)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects of successful dose titration

    Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.

    Time frame: week 1

  2. Number of Subjects of successful dose titration

    Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.

    Time frame: week 4

  3. Number of Subjects of successful dose titration

    Status of successful dose titration. Titration is considered successful when all of the following are met, and ineffective when one of the following is not met: * No additional dose is administered within 2 h of administration of Abstral ODT during maintenance phase; * Numeric Rating Scale scores at 30 mins after administration is reduced by ≥2; Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range) * Adverse drug reactions are tolerable for the subject.

    Time frame: week 12

Secondary outcomes

  1. Status of achievement of Numeric Rating Scale goal

    Status of achievement of Numeric Rating Scale goal set by each subject Numeric Rating Scale is to measure pain intensity in subject by verbally responding to a 10-point Numeric Rating Scale (0=no pain and 10=worst possible pain in total range)

    Time frame: week 1

  2. Abstral ODT maintenance dose

    Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.

    Time frame: week 1(dose titration)

  3. Abstral ODT maintenance dose

    Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.

    Time frame: week 4

  4. Abstral ODT maintenance dose

    Abstral ODT maintenance dose at Week 4 and 12 of treatment, and after dose titration Data will be collected at Week 1 (±3 days), Week 4 (±1 week), and Week 12 (±4 weeks) from the baseline visit according to the circumstances of clinical practice.

    Time frame: week 12

  5. Brief Pain Inventory-Korean and Pain Diary values and changes

    Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)

    Time frame: week 1

  6. Brief Pain Inventory-Korean and Pain Diary values and changes

    Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)

    Time frame: week 4

  7. Brief Pain Inventory-Korean and Pain Diary values and changes

    Brief Pain Inventory-Korean and Pain Diary values (maximum pain intensity of all incidences of breakthrough pain, pain intensity difference at 30min, pain intensity difference at 60 mins, quality of sleep, etc.) and changes. Brief Pain Inventory-Korean is to measure pain intensity in subject by verbally responding to a 10-point scale(0=no pain and 10=worst possible pain in total range)

    Time frame: week 12

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
08

References and documents

Publications

  • Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010 Jun;149(3):476-482. doi: 10.1016/j.pain.2010.02.035. Epub 2010 Mar 16. PubMed 20236762 ↗
  • Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009 Apr;13(4):331-8. doi: 10.1016/j.ejpain.2008.06.014. Epub 2008 Aug 15. PubMed 18707904 ↗
  • Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, Caraceni A, Kaasa S, Dragani TA, Azzarello G, Luzzani M, Cavanna L, Bandieri E, Gamucci T, Lipari G, Di Gregorio R, Valenti D, Reale C, Pavesi L, Iorno V, Crispino C, Pacchioni M, Apolone G; CERP STUDY OF PAIN GROUP (List of collaborators). Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids. Ann Oncol. 2016 Jun;27(6):1107-1115. doi: 10.1093/annonc/mdw097. Epub 2016 Mar 2. PubMed 26940689 ↗
  • Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014 Jan;47(1):57-76. doi: 10.1016/j.jpainsymman.2013.02.015. Epub 2013 Jun 21. PubMed 23796584 ↗
  • Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990 Jun;41(3):273-281. doi: 10.1016/0304-3959(90)90004-W. PubMed 1697056 ↗
  • Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999 May;81(1-2):129-34. doi: 10.1016/s0304-3959(99)00006-8. PubMed 10353500 ↗
  • Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncology (Williston Park). 1989 Aug;3(8 Suppl):25-9. PubMed 2484297 ↗
  • Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000 Aug;20(2):87-92. doi: 10.1016/s0885-3924(00)00161-5. Erratum In: J Pain Symptom Manage 2001 Mar;21(3):265. PubMed 10989246 ↗
  • Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, Kim SY, Yim CY, Sohn CH, Song HS, Hong YS. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage. 2011 Jan;41(1):93-103. doi: 10.1016/j.jpainsymman.2010.03.025. Epub 2010 Sep 26. PubMed 20870388 ↗
  • Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA, Lickiss N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano JA, Andersen H, Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere P, Poyhia R, Vuorinen E, Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere JY, Hege-Scheuing G, Bowdler I, Helbing F, Kostner E, Radbruch L, Kastrinaki K, Shah S, Vijayaram S, Sharma KS, Devi PS, Jain PN, Ramamani PV, Beny A, Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug S, Engstrand P, Ovalle AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov A, Vaisman M, Rudoy S, Gomez Sancho M, Vila P, Trelis J, Chaudakshetrin P, Koh ML, Van Dongen RT, Vielvoye-Kerkmeer A, Boswell MV, Elliott T, Hargus E, Lutz L; Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004 Apr;18(3):177-83. doi: 10.1191/0269216304pm890oa. PubMed 15198130 ↗
  • Boceta J, De la Torre A, Samper D, Farto M, Sanchez-de la Rosa R. Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. Clin Transl Oncol. 2016 Nov;18(11):1088-1097. doi: 10.1007/s12094-016-1490-4. PubMed 26856600 ↗
  • Coluzzi PH. Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care. 1998 Jan-Feb;15(1):13-22. doi: 10.1177/104990919801500105. PubMed 9468974 ↗
  • Patt RB, Ellison NM. Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology (Williston Park). 1998 Jul;12(7):1035-46; discussion 1049-52. PubMed 9684277 ↗
  • Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001 Mar;91(1-2):123-30. doi: 10.1016/s0304-3959(00)00427-9. PubMed 11240084 ↗
  • Lennernas B, Hedner T, Holmberg M, Bredenberg S, Nystrom C, Lennernas H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005 Feb;59(2):249-53. doi: 10.1111/j.1365-2125.2004.02264.x. PubMed 15676050 ↗
  • Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009 Dec;25(12):2877-85. doi: 10.1185/03007990903368310. PubMed 19814586 ↗
  • Takigawa C, Goto F, Tanda S, Shima Y, Yomiya K, Matoba M, Adachi I, Yoshimoto T, Eguchi K. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation. Jpn J Clin Oncol. 2015 Jan;45(1):67-74. doi: 10.1093/jjco/hyu167. Epub 2014 Nov 7. PubMed 25381384 ↗
  • Nalamachu SR, Rauck RL, Wallace MS, Hassman D, Howell J. Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies. Pain Pract. 2012 Jul;12(6):449-56. doi: 10.1111/j.1533-2500.2011.00525.x. Epub 2012 Jan 9. PubMed 22226371 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jun 2019, 23 months.

Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Mar 29, 2019
StartActual
Jul 4, 2017
Primary completionActual
Jun 28, 2019
CompletionActual
Jun 28, 2019
Last update
May 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03895762
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Jul 4, 2017
Primary completion
Jun 28, 2019
Completion
Jun 28, 2019
Last update
May 5, 2022

Study contacts

Jin-Seok Ahn
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion